Comparative Pharmacology
Head-to-head clinical analysis: HUMALOG versus HUMALOG MIX 50 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMALOG versus HUMALOG MIX 50 50.
HUMALOG vs HUMALOG MIX 50/50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin lispro is a rapid-acting insulin analog that lowers blood glucose by binding to insulin receptors on skeletal muscle and adipocytes, leading to increased glucose uptake and reduced hepatic glucose production.
Insulin analog that binds to insulin receptors, activating downstream signaling pathways to promote glucose uptake, glycogen synthesis, and lipogenesis, and inhibit gluconeogenesis and ketogenesis.
Subcutaneous injection: 0.2-1.0 units/kg/day divided into 3 or more doses, given within 15 minutes before or immediately after a meal. Typical total daily dose range 0.5-1.0 units/kg/day.
Subcutaneous injection of 0.2 to 0.6 units/kg/day divided into 3 or more doses, with the preprandial dose based on blood glucose monitoring. Typical total daily dose is 0.5 units/kg/day. Administer within 15 minutes before or after a meal.
None Documented
None Documented
Subcutaneous: 0.5-1.0 hour (insulin lispro); longer with renal impairment (up to 1.5-3 hours).
Subcutaneous injection: terminal half-life approximately 1-2 hours, reflecting clearance from the injection site and systemic elimination. Clinical context: allows twice-daily dosing.
Renal: 60-80% as unchanged drug; biliary/fecal: minor (<10%).
Primarily via renal excretion of insulin degradation products; less than 1% excreted as unchanged insulin. No significant biliary or fecal elimination.
Category C
Category C
Insulin
Insulin